{"entity":{"id":"paul-baas","kind":"person","name":"Paul Baas","aka":[],"tldr":"Led CheckMate 743, the trial that gave mesothelioma its first new first-line therapy in 16 years.","summary":"Paul Baas was principal investigator of CheckMate 743, which showed nivolumab plus ipilimumab improves overall survival over platinum-pemetrexed in unresectable malignant pleural mesothelioma, the first positive first-line trial since 2004 and the basis for immunotherapy's approval in the disease. He has led ESMO and IASLC mesothelioma guidelines and chaired the IASLC mesothelioma staging work.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baas%20P%5BAuthor%5D%20mesothelioma%20nivolumab"}],"tags":["mesothelioma","immunotherapy"],"related":[],"cancers":["mesothelioma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","ctla4"],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["nki"],"pathways":[],"terms":[],"trials":["checkmate-743"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Thoracic Oncologist, Netherlands Cancer Institute; Professor, University of Amsterdam","institutionId":"nki","specialisms":["Mesothelioma","Thoracic oncology","Immunotherapy","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baas%20P%5BAuthor%5D%20mesothelioma%20nivolumab"}],"papers":[{"title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(20)32714-8"},{"title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2015,"doi":"10.1093/annonc/mdv199"}],"orcid":"0000-0001-7018-9556"},"route":"/people/paul-baas/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/"}],"trial":[{"id":"checkmate-743","kind":"trial","name":"CheckMate 743","route":"/trials/checkmate-743/"}]}}